JP2025500784A5 - - Google Patents

Info

Publication number
JP2025500784A5
JP2025500784A5 JP2024534144A JP2024534144A JP2025500784A5 JP 2025500784 A5 JP2025500784 A5 JP 2025500784A5 JP 2024534144 A JP2024534144 A JP 2024534144A JP 2024534144 A JP2024534144 A JP 2024534144A JP 2025500784 A5 JP2025500784 A5 JP 2025500784A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/061991 external-priority patent/WO2023105479A1/en
Publication of JP2025500784A publication Critical patent/JP2025500784A/ja
Publication of JP2025500784A5 publication Critical patent/JP2025500784A5/ja
Pending legal-status Critical Current

Links

JP2024534144A 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用 Pending JP2025500784A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163287557P 2021-12-09 2021-12-09
US63/287,557 2021-12-09
US202163290765P 2021-12-17 2021-12-17
US63/290,765 2021-12-17
PCT/IB2022/061991 WO2023105479A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Publications (2)

Publication Number Publication Date
JP2025500784A JP2025500784A (ja) 2025-01-15
JP2025500784A5 true JP2025500784A5 (cg-RX-API-DMAC7.html) 2025-12-12

Family

ID=84537874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534144A Pending JP2025500784A (ja) 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用

Country Status (9)

Country Link
US (2) US20230183360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444426A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500784A (cg-RX-API-DMAC7.html)
KR (1) KR20240112963A (cg-RX-API-DMAC7.html)
AU (1) AU2022407875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241933A1 (cg-RX-API-DMAC7.html)
IL (1) IL313410A (cg-RX-API-DMAC7.html)
MX (1) MX2024007066A (cg-RX-API-DMAC7.html)
WO (1) WO2023105479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547867A (zh) * 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2026022733A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026150367A1 (en) * 2025-01-13 2026-07-16 Janssen Biotech, Inc. Bispecific anti-egfr/c-met antibody-drug conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
BR112022015140A2 (pt) * 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met

Similar Documents

Publication Publication Date Title
JP2024102215A5 (cg-RX-API-DMAC7.html)
JP2023511595A5 (cg-RX-API-DMAC7.html)
JP2020509027A5 (cg-RX-API-DMAC7.html)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2020508317A5 (cg-RX-API-DMAC7.html)
TW201922793A (zh) Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途
JP2024514344A5 (cg-RX-API-DMAC7.html)
JP2023502585A (ja) 癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害
JP2023539589A5 (cg-RX-API-DMAC7.html)
EP4464337A1 (en) Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents
JP2023513297A5 (cg-RX-API-DMAC7.html)
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
WO2017205216A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
CN120437288A (zh) 治疗卵巢癌的药物组合
KR20240046526A (ko) 소세포폐암 치료용 약학적 조성물
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP2025505642A5 (cg-RX-API-DMAC7.html)
CN112007162A (zh) Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
JP2017515843A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2020535180A5 (cg-RX-API-DMAC7.html)
CN111148534A (zh) 抗igf和抗pd-1抗癌组合疗法
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
CN118697865A (zh) 治疗淋巴瘤的药物组合